top of page

Participating Institutions

  • Baylor San Antonio

    • Robert Adam Noel

  • Cedars-Sinai Medical Center

    • Quin Y Liu

  • Children's Hospital Los Angeles

    • Yuhua Zheng

  • Children's Hospital of Pittsburgh

    • Kate Ellery

  • Children’s Hospital Boston

    • Amit Grover

  • Children's Hospital of Wisconsin

    • Praveen Goday

  • Cincinnati Children's Medical Center

    • Maisam Abu-El-Haija

  • Emory University

    • Alvin Jay Freeman

  • Hadassah Medical Center - Mount Scopus Hospital

    • Michael Wilschanski

  • Montreal Children's Hospital

    • Veronique Morinville

  • Nationwide Children's Hospital

    • Cheryl Gariepy

  • Johns Hopkins University

    • Kenneth Ng

  • Ochsner Medical Center

    • Matthew Giefer

  • Indiana University

    • Brian McFerron​

  • Stanford University

    • Zachary Sellers

  • Sydney Children's Hospital

    • Keith Ooi

  • Texas Children's Hospital

    • Douglas Fishman

  • The Children's Hospital of Philadelphia

    • Asim Maqbool

  • The Hospital for Sick Children

    • Tanja Gonska

  • UCSF Benioff Children's Hospital

    • Emily Perito

  • University of Iowa Stead Family Children's Hospital

    • Aliye Uc

  • University of Minnesota Masonic Children's Hospital

    • Sarah Schwarzenberg​

  • University of Colorado Denver

    • Jacob Mark

  • UTSW Children's Medical Center Dallas

    • David Troendle

  • Washington University School of Medicine

    • Mark Lowe

Pediatric Longitudinal Cohort Study of Chronic Pancreatitis (INSPPIRE 2)

​Study Co-Chairs


Study Overview

  • INSPPIRE 2 will enroll a total of 860 patients 0-18 years old with Acute Recurrent Pancreatitis (ARP) and Chronic Pancreatitis (CP). Included in the total are the 502 patients in the INSPPIRE 1 database who are planned to be reenrolled under this protocol over the next 4 years.  Patient questionnaires and physician surveys will be applied at the time of enrollment and annually thereafter as long as possible.  At the first study visit after turning 18 years of age, the patient will sign the informed consent to continue in the study.  Enrollment for INSPPIRE 2 began in July 2017 with 22 international clinical centers. As of July 2019, 438 participants have been enrolled into the study. INSPPIRE 2 will provide the most comprehensive and reliable estimates to characterize the demographics of the pediatric ARP and CP cohort, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer, disease burden and sequelae, and predictors of early onset CP and its sequelae. The established cohort and biorepository will facilitate subsequent studies, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of ARP and CP.

Primary Objectives

  • To comprehensively characterize the pediatric population with Acute Recurrent Pancreatitis (ARP) and Chronic Pancreatitis (CP) and determine predictors of early onset CP and its sequelae.

  • Hypotheses: We hypothesize that childhood onset ARP follows a severe disease course with rapid progression to CP and early development of complications including persistent abdominal pain, growth and nutritional disturbances, exocrine pancreatic insufficiency, glycemic abnormalities, diabetes, repeated hospitalizations and procedures, all of which resulting in socioeconomic burden and an overall impaired quality of life. We also hypothesize that specific risk factors predispose children for early progression from ARP to CP, and specific risk factors predispose children to CP sequelae and high disease burden.


  • Uc A, Perito ER, Pohl JF, Shah U, Abu-El-Haija M, Barth B, Bellin MD, Ellery KM, Fishman DS, Gariepy CE, Giefer MJ, Gonska T, Heyman MB, Himes RW, Husain SZ, Maqbool A, Mascarenhas MR, McFerron BA, Morinville VD, Lin TK, Liu QY, Nathan JD, Rhee SJ, Ooi CY, Sellers ZM, Schwarzenberg SJ, Serrano J, Troendle DM, Werlin SL, Wilschanski M, Zheng Y, Yuan Y, Lowe ME. International Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPIRE 2 From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas, 47:1222-1228, 2018

bottom of page